166953-80-6

Usage

Uses

Used in Flavoring Industry:
Acetic acid, 2-(4-acetyl-2-methylphenoxy)-, methyl ester is used as a flavoring ingredient for its aromatic properties, enhancing the taste and aroma of various food products.
Used in Perfumery Industry:
In the perfumery industry, Acetic acid, 2-(4-acetyl-2-methylphenoxy)-, methyl ester is utilized as a fragrance ingredient, contributing to the creation of complex and appealing scents in perfumes and other scented products.
Used in Cosmetics Industry:
Acetic acid, 2-(4-acetyl-2-methylphenoxy)-, methyl ester is used in the formulation of cosmetics for its aromatic qualities, adding pleasant scents to skincare and beauty products.
Used in Pesticide and Herbicide Applications:
Acetic acid, 2-(4-acetyl-2-methylphenoxy)-, methyl ester is employed as a potential pesticide and herbicide, leveraging its biocidal properties to control pests and unwanted plant growth in agricultural settings.
Used in Antimicrobial and Anti-Fungal Applications:
Due to its antimicrobial and antifungal properties, Acetic acid, 2-(4-acetyl-2-methylphenoxy)-, methyl ester is used in various industrial applications to prevent the growth of harmful microorganisms, ensuring the safety and quality of products in diverse sectors.

InChI:InChI=1/C12H14O4/c1-8-6-10(9(2)13)4-5-11(8)16-7-12(14)15-3/h4-6H,7H2,1-3H3

Upstream product

• 876-02-8 4-hydroxy-3-methylphenyl methyl ketone 
• 96-32-2 bromoacetic acid methyl ester 
• 95-48-7 ortho-cresol 
• 2989-17-5 methyl 2-methylphenoxy acetate 
• 75-36-5 acetyl chloride 

Downstream Products

• 870289-01-3 [4-(5-bromo-4'-methoxy-biphenyl-3-ylmethoxy)-2-methyl-phenoxy]-acetic acid methyl ester 
• 869015-14-5 (4-[3,3-bis-(4-iodophenyl)allyloxy]-2-methylphenoxy)acetic acid methyl ester 
• 869014-75-5 (4-{3,3-bis-[4-(3-pyrrolidin-1-yl-prop-1-ynyl)phenyl]allyloxy}-2-methylphenoxy)acetic acid 
• 869015-29-2 (4-{3,3-bis-[4-(3-pyrrolidin-1-yl-prop-1-ynyl)phenyl]allyloxy}-2-methylphenoxy)acetic acid methyl ester 
• 317318-84-6 GW 0742 

Relevant academic research and scientific papers

Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold

Based on a previously reported phenoxyacetic acid scaffold, compound 7 (HWL-088) has been identified as a superior free fatty acid receptor 1 (FFA1) agonist by comprehensive structure-activity relationship study. Our results indicated that the introduction of ortho-fluoro greatly increased the activity of phenoxyacetic acid series, and the unique structure-activity relationship in biphenyl moiety is different from previously reported FFA1 agonists. Moreover, the modeling study was also performed to better understand the binding mode of present series. Compound 7 significantly improved glucose tolerance both in normal and diabetic models, and even exerted greater potential on glucose control than that of TAK-875. These findings provided a novel candidate HWL-088, which is currently in preclinical study to evaluate its potential for the treatment of diabetes.

Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents

The free fatty acid receptor 1 (FFA1 or GPR40) and peroxisome proliferator-activated receptor δ (PPARδ) have attracted a lot of attention due to their role in promoting insulin secretion and sensibility, respectively, which are two major features of diabetes. Therefore, the dual FFA1/PPARδ agonists would increase insulin secretion and sensibility by FFA1 and PPARδ activation. In this study, we hybrid FFA1 agonist AM-4668 with PPARδ agonist GW501516, leading to the identification of orally bioavailable dual agonist 32, which revealed high selectivity over other PPARs. Moreover, compound 32 exhibited good pharmacokinetic profiles with high plasma concentration, sustained half-life and low clearance in vivo. During the hypoglycemic test, a dual agonist 32 enhanced the tolerance of ob/ob mice for glucose loading in a dose-dependent manner. Our results suggest that dual FFA1/PPARδ agonist could be a valuable therapy for type 2 diabetes.

Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50 = 62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

Novel compounds, their preparation and use

Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype.

NOVEL COMPOUNDS, THEIR PREPARATION AND USE

Novel compounds of the general formula (I), the use of these compounds as phar- maceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPARδ and should be useful for treating conditions mediated by the same.

PROCESS FOR PREPARING PHENOXY ACETIC ACID DERIVATIVES

The preparation of an intermediate, a process for the preparation thereof and the process of preparing [4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-2-methyl-phenoxy]-acetic acid using this intermediate are described.

1,3,5-Trisubstituted aryls as highly selective PPARδ agonists

A series of highly potent and selective PPARδ agonists is described using the known non-selective ligand GW2433 as a structural template. Compound 1 is bioavailable, potent (10 nM), and shows no cross-activity with other PPAR subtypes up to 10 μM, making it a useful tool in studying the biological effects of selective PPARδ activation.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) fam

PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS

Novel compounds of the general formula (I), the use of these compounds as phar- maceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.